Clinical Trial Update: Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors [Phase 2]

View source ↗

Summary

Phase 2 study investigating brentuximab vedotin with bevacizumab in refractory CD-30 positive germ cell tumors was terminated; results posted (2020-12-10).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Germ Cell Tumor | Phase 2 | Status: TERMINATED | Results posted: 2020-12-10